NRCS
NOTICE OF REGISTRATION CONFIRMATION EMAILED
01/02/2024
Back to search
Official data from USPTO
THE GENE TO ANTIBODY COMPANY
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
THE GENE TO ANTIBODY COMPANY
ST13
US500000097382404Class
40, 42
Filing
97382404
Registration
7264779
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
16
Latest update
01/02/2024
Trademark type
Word
Nice classes
40, 42
Filing date
04/26/2022
Registration date
01/02/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/02/2024
Last transaction
01/02/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Supplemental Register
First use anywhere
11/01/2020
First use in commerce
11/01/2020
Drawing code
4
Owner type
16
Owner location
Fargo, ND
Examiner
STURMAN, MELISSA
Law office
N70
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Genovac Antibody Discovery LLC
Representatives
Thomas Kading FARGO PATENT AND BUSINESS LAW, PLLC
Technical classification
Nice Classes
Class 40Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 40
Biomanufacturing for othersmanufacturing of antibodiesproteinsplasmids using biological organisms in the manufacturing process
Class 42
Biotechnology research; Development of new technology for others in the field of biotechnology and pharmaceuticals; Laboratory research services relating to pharmaceuticals; Pharmaceutical research and development; Pharmaceutical research services; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Research on the subject of pharmaceuticals; Research and development in the pharmaceutical and biotechnology fields; Testinginspectionresearchdevelopment of pharmaceutical preparations for gene therapy; Providing information on the subject of scientific research in the field of biochemistry and biotechnology
Publications
History of USPTO decisions and trademark events.
16 publications found
R.SR
REGISTERED-SUPPLEMENTAL REGISTER
01/02/2024
CNTA
APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER
04/26/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
04/26/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
04/26/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
04/26/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
04/26/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/15/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/14/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/14/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
02/21/2023
GNRT
NON-FINAL ACTION E-MAILED
02/21/2023
CNRT
NON-FINAL ACTION WRITTEN
02/21/2023
DOCK
ASSIGNED TO EXAMINER
02/13/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/02/2022
NWAP
NEW APPLICATION ENTERED
04/29/2022
Continuous trademark protection
Get notified about every new filing that threatens THE GENE TO ANTIBODY COMPANY or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.